|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SAT1 |
Gene summary for SAT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SAT1 | Gene ID | 6303 |
| Gene name | spermidine/spermine N1-acetyltransferase 1 | |
| Gene Alias | DC21 | |
| Cytomap | Xp22.11 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P21673 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6303 | SAT1 | GSM4909281 | Human | Breast | IDC | 5.70e-11 | -2.90e-01 | 0.21 |
| 6303 | SAT1 | GSM4909282 | Human | Breast | IDC | 4.22e-09 | 1.96e-01 | -0.0288 |
| 6303 | SAT1 | GSM4909285 | Human | Breast | IDC | 1.38e-25 | -2.64e-01 | 0.21 |
| 6303 | SAT1 | GSM4909286 | Human | Breast | IDC | 6.89e-26 | -2.94e-01 | 0.1081 |
| 6303 | SAT1 | GSM4909287 | Human | Breast | IDC | 2.72e-20 | -6.38e-01 | 0.2057 |
| 6303 | SAT1 | GSM4909288 | Human | Breast | IDC | 3.51e-07 | -8.91e-01 | 0.0988 |
| 6303 | SAT1 | GSM4909289 | Human | Breast | IDC | 3.73e-02 | -6.20e-01 | 0.1064 |
| 6303 | SAT1 | GSM4909290 | Human | Breast | IDC | 5.34e-15 | -4.45e-01 | 0.2096 |
| 6303 | SAT1 | GSM4909291 | Human | Breast | IDC | 3.98e-13 | -5.77e-01 | 0.1753 |
| 6303 | SAT1 | GSM4909293 | Human | Breast | IDC | 1.41e-31 | -6.00e-01 | 0.1581 |
| 6303 | SAT1 | GSM4909294 | Human | Breast | IDC | 4.15e-27 | -9.59e-01 | 0.2022 |
| 6303 | SAT1 | GSM4909295 | Human | Breast | IDC | 1.22e-07 | -5.45e-01 | 0.0898 |
| 6303 | SAT1 | GSM4909296 | Human | Breast | IDC | 5.47e-09 | -4.45e-01 | 0.1524 |
| 6303 | SAT1 | GSM4909297 | Human | Breast | IDC | 7.74e-32 | -9.58e-01 | 0.1517 |
| 6303 | SAT1 | GSM4909298 | Human | Breast | IDC | 4.14e-39 | -8.87e-01 | 0.1551 |
| 6303 | SAT1 | GSM4909299 | Human | Breast | IDC | 1.44e-13 | -3.17e-01 | 0.035 |
| 6303 | SAT1 | GSM4909301 | Human | Breast | IDC | 3.92e-08 | -3.72e-01 | 0.1577 |
| 6303 | SAT1 | GSM4909302 | Human | Breast | IDC | 1.86e-14 | -4.14e-01 | 0.1545 |
| 6303 | SAT1 | GSM4909304 | Human | Breast | IDC | 9.00e-34 | -7.99e-01 | 0.1636 |
| 6303 | SAT1 | GSM4909305 | Human | Breast | IDC | 5.48e-14 | -3.56e-01 | 0.0436 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042401 | Breast | Precancer | cellular biogenic amine biosynthetic process | 7/1080 | 37/18723 | 4.68e-03 | 3.60e-02 | 7 |
| GO:0009309 | Breast | Precancer | amine biosynthetic process | 7/1080 | 38/18723 | 5.46e-03 | 4.01e-02 | 7 |
| GO:00065963 | Breast | Precancer | polyamine biosynthetic process | 4/1080 | 14/18723 | 6.92e-03 | 4.67e-02 | 4 |
| GO:00424011 | Breast | IDC | cellular biogenic amine biosynthetic process | 8/1434 | 37/18723 | 6.04e-03 | 4.33e-02 | 8 |
| GO:00093091 | Breast | IDC | amine biosynthetic process | 8/1434 | 38/18723 | 7.15e-03 | 4.92e-02 | 8 |
| GO:00424012 | Breast | DCIS | cellular biogenic amine biosynthetic process | 8/1390 | 37/18723 | 5.01e-03 | 3.72e-02 | 8 |
| GO:00093092 | Breast | DCIS | amine biosynthetic process | 8/1390 | 38/18723 | 5.94e-03 | 4.25e-02 | 8 |
| GO:0006596 | Colorectum | MSS | polyamine biosynthetic process | 7/3467 | 14/18723 | 7.51e-03 | 4.72e-02 | 7 |
| GO:00065952 | Endometrium | EEC | polyamine metabolic process | 7/2168 | 18/18723 | 2.76e-03 | 1.97e-02 | 7 |
| GO:00086525 | Esophagus | ESCC | cellular amino acid biosynthetic process | 51/8552 | 76/18723 | 1.30e-04 | 8.88e-04 | 51 |
| GO:00067671 | Esophagus | ESCC | water-soluble vitamin metabolic process | 41/8552 | 59/18723 | 1.84e-04 | 1.17e-03 | 41 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00067661 | Esophagus | ESCC | vitamin metabolic process | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:19016075 | Esophagus | ESCC | alpha-amino acid biosynthetic process | 45/8552 | 68/18723 | 5.13e-04 | 2.84e-03 | 45 |
| GO:19016174 | Esophagus | ESCC | organic hydroxy compound biosynthetic process | 128/8552 | 237/18723 | 5.86e-03 | 2.16e-02 | 128 |
| GO:0009110 | Esophagus | ESCC | vitamin biosynthetic process | 15/8552 | 20/18723 | 7.60e-03 | 2.71e-02 | 15 |
| GO:0009310 | Liver | NAFLD | amine catabolic process | 9/1882 | 29/18723 | 1.59e-03 | 1.71e-02 | 9 |
| GO:0042402 | Liver | NAFLD | cellular biogenic amine catabolic process | 8/1882 | 27/18723 | 3.97e-03 | 3.34e-02 | 8 |
| GO:0006595 | Liver | Cirrhotic | polyamine metabolic process | 12/4634 | 18/18723 | 2.07e-04 | 1.90e-03 | 12 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421610 | Breast | Precancer | Ferroptosis | 11/684 | 41/8465 | 2.95e-04 | 2.45e-03 | 1.88e-03 | 11 |
| hsa0421613 | Breast | Precancer | Ferroptosis | 11/684 | 41/8465 | 2.95e-04 | 2.45e-03 | 1.88e-03 | 11 |
| hsa0421623 | Breast | IDC | Ferroptosis | 12/867 | 41/8465 | 5.87e-04 | 4.89e-03 | 3.66e-03 | 12 |
| hsa0421633 | Breast | IDC | Ferroptosis | 12/867 | 41/8465 | 5.87e-04 | 4.89e-03 | 3.66e-03 | 12 |
| hsa0421642 | Breast | DCIS | Ferroptosis | 12/846 | 41/8465 | 4.69e-04 | 3.69e-03 | 2.72e-03 | 12 |
| hsa0421652 | Breast | DCIS | Ferroptosis | 12/846 | 41/8465 | 4.69e-04 | 3.69e-03 | 2.72e-03 | 12 |
| hsa04216 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa00330 | Colorectum | AD | Arginine and proline metabolism | 23/2092 | 50/8465 | 8.27e-04 | 5.90e-03 | 3.76e-03 | 23 |
| hsa042161 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa003301 | Colorectum | AD | Arginine and proline metabolism | 23/2092 | 50/8465 | 8.27e-04 | 5.90e-03 | 3.76e-03 | 23 |
| hsa003302 | Colorectum | SER | Arginine and proline metabolism | 17/1580 | 50/8465 | 7.12e-03 | 3.77e-02 | 2.74e-02 | 17 |
| hsa003303 | Colorectum | SER | Arginine and proline metabolism | 17/1580 | 50/8465 | 7.12e-03 | 3.77e-02 | 2.74e-02 | 17 |
| hsa003304 | Colorectum | MSS | Arginine and proline metabolism | 23/1875 | 50/8465 | 1.52e-04 | 1.24e-03 | 7.61e-04 | 23 |
| hsa042162 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
| hsa003305 | Colorectum | MSS | Arginine and proline metabolism | 23/1875 | 50/8465 | 1.52e-04 | 1.24e-03 | 7.61e-04 | 23 |
| hsa042163 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
| hsa042164 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
| hsa003306 | Colorectum | FAP | Arginine and proline metabolism | 16/1404 | 50/8465 | 5.33e-03 | 2.10e-02 | 1.27e-02 | 16 |
| hsa042165 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
| hsa003307 | Colorectum | FAP | Arginine and proline metabolism | 16/1404 | 50/8465 | 5.33e-03 | 2.10e-02 | 1.27e-02 | 16 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SAT1 | SNV | Missense_Mutation | c.167T>C | p.Val56Ala | p.V56A | P21673 | protein_coding | deleterious(0) | possibly_damaging(0.667) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SAT1 | SNV | Missense_Mutation | c.442C>A | p.Leu148Met | p.L148M | P21673 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| SAT1 | SNV | Missense_Mutation | c.184N>C | p.Glu62Gln | p.E62Q | P21673 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-BH-A0C7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| SAT1 | insertion | Frame_Shift_Ins | novel | c.420_421insA | p.Arg142LysfsTer6 | p.R142Kfs*6 | P21673 | protein_coding | TCGA-EA-A44S-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
| SAT1 | SNV | Missense_Mutation | novel | c.449N>T | p.Ser150Ile | p.S150I | P21673 | protein_coding | deleterious(0.04) | benign(0.2) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SAT1 | SNV | Missense_Mutation | c.13N>A | p.Val5Met | p.V5M | P21673 | protein_coding | tolerated(0.22) | benign(0.087) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SAT1 | SNV | Missense_Mutation | c.362G>A | p.Arg121His | p.R121H | P21673 | protein_coding | tolerated(0.34) | benign(0.006) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SAT1 | SNV | Missense_Mutation | c.362N>A | p.Arg121His | p.R121H | P21673 | protein_coding | tolerated(0.34) | benign(0.006) | TCGA-CI-6620-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Ancillary | leucovorin | PD | |
| SAT1 | deletion | Frame_Shift_Del | c.117delA | p.Asp40IlefsTer3 | p.D40Ifs*3 | P21673 | protein_coding | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| SAT1 | SNV | Missense_Mutation | novel | c.29N>T | p.Thr10Ile | p.T10I | P21673 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |